Henry Schein’s (HSIC) “Buy” Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of Henry Schein (NASDAQ:HSIC) in a report published on Wednesday morning,Benzinga reports. The brokerage currently has a $100.00 price target on the stock.

Several other research analysts have also weighed in on the stock. Piper Sandler increased their price objective on shares of Henry Schein from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Citigroup began coverage on shares of Henry Schein in a report on Wednesday, April 15th. They issued a “buy” rating and a $100.00 target price for the company. Mizuho dropped their price target on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. UBS Group reaffirmed a “neutral” rating and set a $89.00 price target (up from $85.00) on shares of Henry Schein in a research note on Tuesday, July 28th. Finally, Robert W. Baird set a $97.00 price target on shares of Henry Schein in a report on Wednesday, May 6th. Eight research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Henry Schein currently has a consensus rating of “Hold” and a consensus price target of $92.27.

Henry Schein Stock Performance

Henry Schein stock opened at $88.13 on Wednesday. The firm has a market capitalization of $9.82 billion, a P/E ratio of 25.69, a PEG ratio of 1.68 and a beta of 0.80. The stock has a fifty day moving average price of $83.49 and a 200 day moving average price of $78.67. Henry Schein has a 52 week low of $61.94 and a 52 week high of $92.18. The company has a current ratio of 1.32, a quick ratio of 0.75 and a debt-to-equity ratio of 0.60.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.03. The firm had revenue of $3.46 billion for the quarter, compared to the consensus estimate of $3.37 billion. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.10 earnings per share. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Equities research analysts anticipate that Henry Schein will post 5.35 earnings per share for the current year.

Insider Activity

In other Henry Schein news, Director William K. Daniel acquired 10,000 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $69.19 per share, with a total value of $691,900.00. Following the completion of the transaction, the director directly owned 20,000 shares of the company’s stock, valued at approximately $1,383,800. The trade was a 100.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.89% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. CYBER HORNET ETFs LLC acquired a new position in shares of Henry Schein during the second quarter worth about $25,000. MUFG Securities EMEA plc purchased a new stake in shares of Henry Schein during the 2nd quarter valued at about $27,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Henry Schein during the 4th quarter valued at about $30,000. Federated Hermes Inc. acquired a new position in Henry Schein during the 4th quarter worth approximately $32,000. Finally, Los Angeles Capital Management LLC acquired a new position in Henry Schein during the 4th quarter worth approximately $37,000. 96.62% of the stock is owned by hedge funds and other institutional investors.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.